Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 10NIH 3INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Endocrine 1

Conditions

Neuroblastoma 2Recurrence 1Pheochromocytoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × 3-Iodobenzylguanidine × Clear all
NCT00028106 2017-07-02

131MIBG to Treat Malignant Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled
Endocrine

Neoplasm Metastasis, Neoplasms, Pheochromocytoma

NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

NCT00013806 2005-06-24

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

National Center for Research Resources (NCRR)

Phase 2 Unknown
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡